# IPI-504 in NSCLC Patients With ALK Translocations

> **NCT01228435** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 3 (actual)

## Conditions studied

- Lung Cancer
- Stage IIIb Lung Cancer
- Stage IV Lung Cancer

## Interventions

- **DRUG:** IPI-504

## Key facts

- **NCT ID:** NCT01228435
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228435, "IPI-504 in NSCLC Patients With ALK Translocations". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01228435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*